Hyperbaric Oxygen Therapy for Idiopathic Sudden Sensorineural Hearing Loss
Patient Assessment and Diagnostic Confirmation
- The American Academy of Otolaryngology-Head and Neck Surgery confirms the diagnosis of idiopathic sudden sensorineural hearing loss (ISSNHL) with hearing loss greater than 30 dB affecting at least 3 consecutive frequencies, negative MRI ruling out retrocochlear pathology, and failure to respond adequately to both systemic and intratympanic steroids 1, 2, 3
- Patients with ISSNHL typically present with moderate to profound hearing loss and 0% speech discrimination in the affected ear, as confirmed by audiometric testing 1, 2
Medical Necessity Criteria
- The American Academy of Otolaryngology-Head and Neck Surgery recommends HBOT as a salvage therapy for patients with ISSNHL who have failed oral and intratympanic steroids, with treatment initiated within 3 months of symptom onset 1, 2
- HBOT may be offered to patients with ISSNHL greater than 30 dB affecting 3 consecutive frequencies, who have failed standard therapies 1, 2
Evidence for Efficacy
- The 2019 American Academy of Otolaryngology-Head and Neck Surgery guidelines recommend HBOT combined with steroid therapy as a salvage option within 1 month of ISSNHL onset 2
Treatment Protocol
- The recommended HBOT protocol includes up to 20 sessions within 3 months of symptom onset, with earlier intervention associated with better outcomes 1, 2, 4
Potential Risks and Considerations
- Potential adverse effects of HBOT include difficulty equalizing pressure in the middle ear (up to 17% of patients), Eustachian tube dysfunction, ear or sinus barotrauma (approximately 6.25% of ISSNHL patients), and confinement anxiety during treatment 4
- These risks are generally considered acceptable given the potential benefit for hearing recovery, especially in patients who have already failed standard therapies 2